Exagen Inc. (XGN) is an innovative company that is making significant contributions to the healthcare industry by revolutionizing patient care with cutting-edge testing procedures. It operates as a commercial-stage diagnostics company with a focus on autoimmune diseases. Founded in 2002 and based in Vista, California, the publicly-traded company develops, manufactures, and markets diagnostic tests under the AVISE® brand, aimed at providing more accurate, timely, and cost-effective diagnoses for complex autoimmune conditions.
Exagen’s flagship product is AVISE CTD, a proprietary diagnostic test that helps physicians diagnose and manage systemic lupus erythematosus (SLE) and other connective tissue diseases. Over the years, the company has expanded its product line to include tests for rheumatoid arthritis, vasculitis, and antiphospholipid syndrome, among other conditions.
The company stands out for its commitment to cutting-edge research and development, often in partnership with leading medical institutions. Exagen’s pioneering spirit and dedication to delivering quality care to patients with autoimmune diseases is evident in their extensive research collaborations, numerous patents, and a steady stream of innovative diagnostic tests.
Exagen’s contribution to the healthcare industry is not only limited to diagnostics. It has launched a proprietary disease activity metric, "Cell-bound complement activation products" (CB-CAPs), that like the AVISE tests, enables clinicians to effectively monitor disease activity in patients with systemic lupus erythematosus, helping guide treatment decisions and improve patient outcomes.
Exagen’s approach places the patient at the center of its innovation endeavors. Through the delivery of highly specific and sensitive diagnostic testing, they aim to personalize patient care and management, improve health outcomes, and eventually reduce costs for both patients and healthcare providers. Bridging the gap between medical research and patient care, Exagen continues to drive advancement in autoimmune disease diagnosis and monitoring, playing a vital role in the journey to improve individual patient care in a challenging and evolving therapeutic area.
A key strength lies in the company's solid reputation for accuracy and reliability. Alongside their robust product development pipeline and their partnerships with significant industry players, this positions them firmly at the forefront of the autoimmune diagnostic sector. As a result, Exagen Inc. has quickly become a leader in the diagnostic and healthcare market, cementing their status as a go-to solution for autoimmune disease diagnostics.